PRKAA2 and Stroke: Not surprisingly then, the first evidence that AMPK activation may be deleterious was provided in a stroke model where it was found that pharmacological inhibition of AMPK or ablation of AMPKα2 (but surprisingly not AMPKα1) reduced infarct size [34,35].